Murray Jason Hulse sold $1.6M of PACS

Murray Jason Hulse (Co-Founder, CEO & Chairman) sold 36,692 shares of PACS Group, Inc. (PACS) at an average of $43.08 ($42.48–$43.64, $1.58M total) across 3 trades over 2026-10-06 to 2026-10-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Murray Jason Hulse
Published Oct 7, 2026, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PACS
Bearish
medium confidence
Mentioned
$PACS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACSBearishLow
01

Why it matters

The disclosed sale may influence short‑term sentiment but is unlikely to drive a major price move.

02

Market read

Insider sell of $1.6M is a modest, routine disclosure with limited trading relevance.

03

What to watch

The insider retained a large stake (over 54 million shares) indicating continued confidence.

Relevance 5/10Novelty 4/10Timing: filing date 2026-10-07

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$PACSBearishMedium confidence
Context

Form 4 disclosed Murray Jason Hulse sold 36,692 shares for $1.58M, reducing his stake in PACS Group.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

The sale is sizable for a micro‑cap and was executed via a 10b5‑1 plan, suggesting a planned reduction rather than a reaction to new information.

Market effects

Minimal impact on the broader healthcare services sector.

Limited to U.S. investors tracking PACS.

Low

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Murray Jason Hulse

    Co‑Founder, CEO & Chairman of PACS Group, 10% owner.

  • PACS Group, Inc.

    U.S. listed healthcare services provider (NASDAQ: PACS).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PACSMedAI 8/10

What PACS Group (PACS) Said on Its Q3 Earnings Call

PACS Group reported 196 mature, 90 ramping, and 35 new skilled nursing facilities with occupancy ranging from 76.2% to 93.1%. The company acquired 32 Florida and 10 Texas skilled nursing operations post-quarter. PACS raised its 2026 revenue outlook to $5.95B-$6.05B and adjusted EBITDA to $685M-$695M, citing strength in existing operations and new acquisitions. Operating cash flow was $583.1M for the first nine months of 2026, with $707.4M in available liquidity.

$PACSHighAI 8/10

PACS Group Inc (PACS) (Q3 2026) Earnings Call Highlights: Revenue Tops

PACS Group Inc (NYSE:PACS) reported Q3 2026 revenue growth of 6.4%, with adjusted EBITDA up 33.6% to $175.7M. The company raised full-year guidance, citing strong occupancy and skilled mix improvements. PACS also highlighted a robust acquisition pipeline and integration plans for 31 Eduro facilities. Challenges include lower metrics at newly acquired facilities and ongoing government investigations.

$PACSHigh

Why is PACS stock surging today?

PACS Group Inc (PACS) stock rose 6.0% in after-hours trading after beating Q3 2026 earnings and revenue estimates. The company also raised its full-year 2026 Adjusted EBITDA and revenue guidance. Analysts maintain a 'Moderate Buy' rating with an average price target of $58.80. The surge was driven by company-specific news.